Dazhao Peng

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

NEU1 sustains mitochondria-lysosome contacts to trigger lysosomal Cu²+/cathepsin escape and mitochondrial lysis in glioblastoma (NeuLysis).

NEU1 sustains mitochondria-lysosome contacts to trigger lysosomal Cu²+/cathepsin escape and mitochondrial lysis in glioblastoma (NeuLysis).

Journal: Neuro-oncology

Published: August 30, 2025

Multi-omics analysis identifies CCNB1 as a cell cycle factor driving glioblastoma progression and its inhibition by resveratrol.

Multi-omics analysis identifies CCNB1 as a cell cycle factor driving glioblastoma progression and its inhibition by resveratrol.

Journal: PloS one

Published: August 01, 2025

A novel protein SPECC1-415aa encoded by N6-methyladenosine modified circSPECC1 regulates the sensitivity of glioblastoma to TMZ.

A novel protein SPECC1-415aa encoded by N6-methyladenosine modified circSPECC1 regulates the sensitivity of glioblastoma to TMZ.

Journal: Cellular & molecular biology letters

Published: May 04, 2024

A novel protein encoded by circCOPA inhibits the malignant phenotype of glioblastoma cells and increases their sensitivity to temozolomide by disrupting the NONO-SFPQ complex.

A novel protein encoded by circCOPA inhibits the malignant phenotype of glioblastoma cells and increases their sensitivity to temozolomide by disrupting the NONO-SFPQ complex.

Journal: Cell death & disease

Published: April 24, 2024

Evidences of neurological injury caused by COVID-19 from glioma tissues and glioma organoids.

Evidences of neurological injury caused by COVID-19 from glioma tissues and glioma organoids.

Journal: CNS neuroscience & therapeutics

Published: April 18, 2024

Neuron-like lineage differentiation induced by exogenous Neurexin-1 as a potential therapeutic strategy for glioma.

Neuron-like lineage differentiation induced by exogenous Neurexin-1 as a potential therapeutic strategy for glioma.

Journal: Cancer letters

Published: February 08, 2024

LncRNA HOXA11-AS promotes glioma malignant phenotypes and reduces its sensitivity to ROS via Tpl2-MEK1/2-ERK1/2 pathway.

LncRNA HOXA11-AS promotes glioma malignant phenotypes and reduces its sensitivity to ROS via Tpl2-MEK1/2-ERK1/2 pathway.

Journal: Cell death & disease

Published: June 29, 2022

Corrigendum: Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.

Corrigendum: Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.

Journal: Frontiers in immunology

Published: May 15, 2022

The role of N6-methyladenosine-modified non-coding RNAs in the pathological process of human cancer.

The role of N6-methyladenosine-modified non-coding RNAs in the pathological process of human cancer.

Journal: Cell death discovery

Published: May 07, 2022

CircRNA: An emerging star in the progression of glioma.

CircRNA: An emerging star in the progression of glioma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: April 07, 2022

Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.

Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.

Journal: Frontiers in immunology

Published: January 06, 2022

Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers.

Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers.

Journal: Cancer cell international

Published: August 10, 2021

Showing 1-12 of 12

Last Updated: 09/26/2026